#	Pagina
attuale pagina	/open-h2020/projects/226675/index.html

Opendata, web and dolomites

INDIGO SIGNED

Effective and Affordable Flu Vaccines for the World

Total Cost €

EC-Contrib. €

Partnership

Views

INDIGO project word cloud

Explore the words cloud of the INDIGO project. It provides you a very rough idea of what is the project "INDIGO" about.

epitopes free protected generation affordability realistic clinical proof plans lack immunogenicity decades vaccines instead limited completion lt embark neutralizing collaborate accessibility innovations differ health pandemic casualties limits public countries influenza iia despite 60 recombinant inactivated meet significantly lower seasonal people commercial stimulates vaccination protective needle adjuvant immunization removed effectivity timelines globe india 40 responders combines proven event trials opens 500 global memory vaccinated dose patches intradermal immunological private administration disease confidence builds possibilities chances annually perspective sufficiently self safety 10 flu complexity contra nonclinical vaccine immunity implies parts potent first productive

Project "INDIGO" data sheet

The following table provides information about the project.

Coordinator	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Organization address address: MEIBERGDREEF 15 city: AMSTERDAM postcode: 1105AZ website: www.amc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	16˙000˙968 €
EC max contribution	9˙975˙979 € (62%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2019-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-04-01 to 2025-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Organization address address: MEIBERGDREEF 15 city: AMSTERDAM postcode: 1105AZ website: www.amc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	1˙459˙697.00
2	Universitair Ziekenhuis Gent Universitair Ziekenhuis Gent Organization address address: De Pintelaan 185 city: Gent postcode: 9000 website: http://www.uzgent.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (Gent)	participant	1˙779˙591.00
3	LITEVAX BV LITEVAX BV Organization address address: AKKERSESTRAAT 50 city: OPHEMERT postcode: 4061BJ website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (OPHEMERT)	participant	1˙058˙653.00
4	CELLVAX CELLVAX Organization address address: 19 AVENUE DU PROFESSEUR CADIOT city: MAISONS-ALFORT postcode: 94700 website: www.cellvax-pharma.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (MAISONS-ALFORT)	participant	990˙442.00
5	VIROCLINICS BIOSCIENCES BV VIROCLINICS BIOSCIENCES BV Organization address address: MARCONISTRAAT 16 city: ROTTERDAM postcode: 3029 AK website: www.viroclinics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	944˙990.00
6	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	943˙281.00
7	EPIVAX INC EPIVAX INC Organization address address: 188 VALLEY ST SUITE 424 city: PROVIDENCE postcode: 02909 2468 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (PROVIDENCE)	participant	806˙042.00
8	STANIPHARM STANIPHARM Organization address address: RUE JAQUES MONOD 5 city: CHAMPIGNEULLES postcode: 542500 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (CHAMPIGNEULLES)	participant	740˙250.00
9	UNIVERSITEIT GENT UNIVERSITEIT GENT Organization address address: SINT PIETERSNIEUWSTRAAT 25 city: GENT postcode: 9000 website: http://www.ugent.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GENT)	participant	642˙692.00
10	EXPRES2ION BIOTECHNOLOGIES APS EXPRES2ION BIOTECHNOLOGIES APS Organization address address: AGERN ALLE 1 city: HORSHOLM postcode: 2970 website: www.expres2ionbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HORSHOLM)	participant	610˙337.00
11	CBCI Society for Medical Education CBCI Society for Medical Education Organization address address: St. John's National Academy of Health Sciences city: Bangalore postcode: 560034 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (Bangalore)	participant	0.00
12	CHRISTIAN MEDICAL COLLEGE VELLORE CHRISTIAN MEDICAL COLLEGE VELLORE Organization address address: THORAPADI BAGAYAM city: VELLORE postcode: 632002 website: www.cmch-vellore.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (VELLORE)	participant	0.00
13	CLINICAL DEVELOPMENT SERVICES AGENCY CLINICAL DEVELOPMENT SERVICES AGENCY Organization address address: THSTI BUILDING NCR BIOTECH SCIENCE CLUSTER 3RD MILESTONE GURUGRAM FARIDABAD EXPESSWAY city: FARIDABAD postcode: 121001 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (FARIDABAD)	participant	0.00
14	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH Organization address address: Anusandhan Bhawan, Rafi Marg 2 city: NEW DEHLI postcode: 110001 website: www.csir.res.in contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (NEW DEHLI)	participant	0.00
15	GENNOVA BIOPHARMACEUTICALS LIMITED GENNOVA BIOPHARMACEUTICALS LIMITED Organization address address: EMCURE HOUSE T 184 MIDC BHOSARI city: PUNE postcode: 411026 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (PUNE)	participant	0.00
16	TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE Organization address address: NCR BIOTECH SCIENCE CLUSTER 3RD MILESTONE HARYANA city: FARIDABAD postcode: 121001 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (FARIDABAD)	participant	0.00

Map

Project objective

Despite the availability of flu vaccines for decades, influenza is still an important disease in both developing and developed countries with 500,000 casualties annually and many more people affected. From a global health perspective, the lack of effectivity, availability, affordability and accessibility of flu vaccines significantly limits our ability to respond to the seasonal flu every year and in the event of a pandemic. Currently, a low vaccine effectivity of 40% implies that 60% of vaccinated people are not sufficiently protected, with low confidence further contributing to limited uptake/immunization. In this project, public and private R&D organizations in India, EU and US collaborate on the development of two novel influenza vaccine concepts that meet the requirements of global vaccination, aiming to achieve <10% instead of 60% non-responders, lower costs, and better accessibility. The first approach combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel, potent adjuvant, and will deliver proof-of-concept in Phase I and IIa trials within 5 years. The second approach builds on three innovations: 1) a novel recombinant HA with increased immunogenicity, 2) a potent adjuvant, and 3) an easy, needle-free delivery by intradermal patches. Contra-productive parts of HA will be removed to increase the immunogenicity of neutralizing epitopes. The adjuvant further stimulates protective immunity and immunological memory. The use of intradermal patches opens possibilities for self-administration, which will improve vaccine uptake in developing as well as developed countries. With proven nonclinical immunogenicity and safety, we will embark on clinical development of this concept after completion of the project. These plans differ in complexity and timelines but are realistic with chances to deliver next-generation flu vaccines for the globe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INDIGO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INDIGO" are provided by the European Opendata Portal: CORDIS opendata.